15 analysts have shared their evaluations of Tenet Healthcare THC during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 9 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 3 | 5 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $183.6, along with a high estimate of $217.00 and a low estimate of $140.00. This upward trend is apparent, with the current average reflecting a 1.4% increase from the previous average price target of $181.07.
Deciphering Analyst Ratings: An In-Depth Analysis
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tenet Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jamie Perse | Goldman Sachs | Lowers | Neutral | $140.00 | $196.00 |
| Stephen Baxter | Wells Fargo | Lowers | Equal-Weight | $150.00 | $205.00 |
| John Ransom | Raymond James | Maintains | Outperform | $195.00 | $195.00 |
| Andrew Mok | Barclays | Raises | Overweight | $190.00 | $171.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $205.00 | $195.00 |
| Sarah James | Cantor Fitzgerald | Raises | Overweight | $177.00 | $168.00 |
| Jamie Perse | Goldman Sachs | Raises | Buy | $196.00 | $173.00 |
| Ben Hendrix | RBC Capital | Raises | Outperform | $183.00 | $174.00 |
| David Macdonald | Truist Securities | Raises | Buy | $190.00 | $180.00 |
| A.J. Rice | UBS | Raises | Buy | $217.00 | $197.00 |
| Stephen Baxter | Wells Fargo | Raises | Overweight | $195.00 | $175.00 |
| David Macdonald | Truist Securities | Raises | Buy | $180.00 | $170.00 |
| Matthew Gillmor | Keybanc | Announces | Overweight | $200.00 | - |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $168.00 | $168.00 |
| Sarah James | Cantor Fitzgerald | Maintains | Overweight | $168.00 | $168.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenet Healthcare. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenet Healthcare compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tenet Healthcare's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Tenet Healthcare's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Tenet Healthcare analyst ratings.
Delving into Tenet Healthcare's Background
Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.
Unraveling the Financial Story of Tenet Healthcare
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Tenet Healthcare showcased positive performance, achieving a revenue growth rate of 1.11% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Tenet Healthcare's net margin is impressive, surpassing industry averages. With a net margin of 9.22%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tenet Healthcare's ROE excels beyond industry benchmarks, reaching 12.92%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Tenet Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.61% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Tenet Healthcare's debt-to-equity ratio is below the industry average at 3.36, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: What Are They?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
